오큐젠(OCGN)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $1.06 (+2.91%), 시가총액 $0.49B, 52주 최저~최고 $0.67 ~ $2.48.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt
오큐젠의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackAll Trade에서 실시간으로 확인할 수 있습니다.
오큐젠의 현재 주가는 $1.06 (+2.91%)입니다. BlackAll Trade에서 실시간 시세와 차트를 확인할 수 있습니다.
오큐젠의 시가총액은 약 $0.49B입니다.
Ocugen, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies, biologic, and vaccines that improve patients' health. The company's pi